[HTML][HTML] Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective …
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai, A Liu - BMC cancer, 2023 - Springer
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
[HTML][HTML] Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective …
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai, A Liu - BMC Cancer, 2023 - ncbi.nlm.nih.gov
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai… - BMC Cancer, 2023 - search.ebscohost.com
Background: Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai… - BMC Cancer, 2023 - search.proquest.com
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
[HTML][HTML] Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective …
T Zhou, S Zhu, Q Xiong, J Gan, J Wei… - BMC …, 2023 - bmccancer.biomedcentral.com
Leptomeningeal metastasis (LM) is the most devastating complication of non-small cell lung
cancer (NSCLC), and its incidence is increasing. There is currently no standard treatment for …
cancer (NSCLC), and its incidence is increasing. There is currently no standard treatment for …
Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai, A Liu - BMC Cancer, 2023 - europepmc.org
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai… - BMC …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
[PDF][PDF] Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective …
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai, A Liu - 2023 - bmccancer.biomedcentral.com
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai, A Liu - BMC Cancer, 2023 - europepmc.org
Background Leptomeningeal metastasis (LM) is the most devastating complication of non-
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …
small cell lung cancer (NSCLC), and its incidence is increasing. There is currently no …